Follicular Lymphoma (FL)
Conditions
Keywords
relapsed or refractory follicular lymphoma, r/r, FL, CAR-T, tisagenlecleucel, CTL019, phase III, standard of care, SOC
Brief summary
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
Detailed description
The purpose of this phase III study is to verify the clinical benefit of tisagenlecleucel for the treatment of r/r FL by comparing the tisagenlecleucel treatment strategy to standard of care therapy in patients with r/r FL after two or more lines of systemic therapy, with progression-free survival (PFS) as the primary endpoint. The primary objective is to demonstrate superiority of the tisagenlecleucel treatment strategy over standard of care (SOC) therapy with respect to progression-free survival (PFS) determined by blinded independent review committee (BIRC) based on the Lugano response criteria. Participants randomized to Arm A (tisagenlecleucel treatment) will receive a single infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells. Participants randomized to Arm B (Standard of Care) will receive R2 or R-CHOP based on investigator choice and this has to be determined prior to randomization.
Interventions
BIOLOGICALTisagenlecleucel
Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells taken intravenously (i.v.).
DRUGLenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
DRUGRituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) OR Cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine). OR Bendamustine 90 mg/m\^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)
OTHERCorticosteroids and/or Radiation (Bridging therapy)
Corticosteroids and/or Radiation
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years at the date of signing the informed consent form. 2. Follicular lymphoma grade 1, 2, or 3A confirmed histologically after latest relapse (local assessment). 3. Relapsed or refractory disease after a second or later line of systemic therapy including an anti-CD20 antibody and an alkylating agent. 4. Disease that is both active on Positron emission tomography (PET) scan (defined as a score of 4 or 5 on the Deauville 5-point scale) and measurable on Computed tomography (CT) scan. 5. ECOG performance status of 0, 1 or 2 at screening. 6. Adequate hematologic, renal, hepatic and pulmonary organ function at screening. 7. Must meet the institutional criteria to undergo leukapheresis (unless historical leukapheresis is available). 8. Must be eligible for treatment with the selected standard of care regimen.
Exclusion criteria
1. Follicular lymphoma grade 3B or evidence of histologic transformation. 2. Prior treatment with anti-CD19 therapy, gene therapy, or adoptive T-cell therapy. 3. Active CNS involvement by malignancy. 4. Clinically significant active infection, presence of Human immunodeficiency virus (HIV) antibody or active hepatitis B or C. 5. Active neurological autoimmune or inflammatory disorders (e.g., Guillain-Barré syndrome). 6. Investigational medicinal product within the last 30 days or five half-lives (whichever is longer) prior to randomization. 7. Clinically significant cardiovascular conditions such as acute coronary syndrome, significant cardiac arrhythmias, heart failure or decreased LVEF. Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) determined by blinded independent review committee (BIRC) | 5 years | Progression free survival (PFS) based on Lugano response criteria, defined as time from randomization to the first of the following events to occur: * progressive disease (by BIRC) * death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete response rate (CRR) as assessed by BIRC (Key Secondary) | 5 years | CRR: The proportion of participants with BOR of complete response (CR) |
| Overall response rate (ORR) by BIRC | 5 years | ORR: The proportion of participants with BOR of either CR or partial response (PR) |
| Overall survival (OS) | 5 years | OS: Time from randomization to date of death due to any cause |
| Time to next anti-lymphoma treatment (TTNT) | 5 years | TTNT: Time from randomization until start of new anticancer therapy or death due to any cause. |
| Duration of Response (DOR) | 5 years | Time from the date of first documented BIRC response of CR or PR to the date of first documented progression by BIRC or any cause of death |
| Pre-existing (prior to treatment) and treatment-induced anti-mCAR antibodies (humoral immunogenicity) | 5 years | Summarize percentage of patients with pre-existing and treatment-induced anti-mCAR antibodies, and relate the antibody responses with CAR expansion, efficacy, and safety endpoints. |
| CAR transgene levels, as measured by quantitative polymerase chain reaction (qPCR), in peripheral blood, bone marrow (and other tissues, if available) | 5 years | Summary of transgene levels by timepoints and by clinical responses, cellular kinetic parameters will be derived using non-compartmental analysis from time course of transgene levels and will be summarized by clinical responses. |
| Replication competent lentivirus (RCL) by VSV-g qPCR in participants receiving tisagenlecleucel | 5 years | This is to assess presence of (Replication competent lentivirus) RCL in participants receiving tisagenlecleucel by VSV-g qPCR |
Countries
Australia, Austria, Canada, Czechia, Hungary, Poland, Singapore, Slovakia, South Korea, Spain, Taiwan
Contacts
STUDY_DIRECTORNovartis Pharmaceuticals
Novartis Pharmaceuticals
Outcome results
None listed